Ann: Appendix 4C - quarterly, page-60

not sure why you think it’s great. 
The sale of IP was known. 
Main new item seems to be that income from product sales appears to have fallen at time of increased interest payments. Will have to wait until next report at end of this month when they will hopefully clarify. 

Key worry is cash burn. Cash reserves crucial at this stage of biotech. Over past 6 months close to $50m spend, MSB’s borrowed cash won’t last long at this rate. In weeks cash will be less than debt. Already borrowing at 15% which seems crazy. A lot of comment here that shorters only here to manipulate, but generally for shorters to come in they need to be convinced company is in a fragile position. 
Need a deal or approval to come through ASAP, SI has history of pulling something out of the hat, has his pitching run its course due to backer losses over the past few years or perhaps he can do it again.